Focused on oncology, WILEX develops diagnostic and therapeutic product candidates based on antibodies, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform.


Latest News

25.02.2015: WILEX subsidiary Heidelberg Pharma receives research grant from the European Union. WILEX AG today announced that its subsidiary Heidelberg Pharma has been awarded a research grant from the European Union as part of the European Training Network (ETN) MAGICBULLET....More


Seite gelesen: 233669 | Heute: 11